Taken together, our results suggest that USP22 promotes NSCLC cell growth in vitro and NSCLC tumorigenesis in vivo, and these effects are through MDMX up-regulation and subsequent p53 inhibition. The gene discussed is TP53; the disease is non-small cell lung carcinoma.